Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy

Abdullah Al Emran¹, Aniruddha Chatterjee², Euan J Rodger³, Jessamy C Tiffen⁴, Stuart J Gallagher⁴, Michael R Eccles⁵, Peter Hersey⁶

Affiliations

¹ Melanoma Immunology and Oncology Group, The Centenary Institute, University of Sydney, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia; These authors contributed equally.
² Department of Pathology, Dunedin School of Medicine, University of Otago, 270 Great King Street, Dunedin 9054, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, Level, 3A Symonds Street, Auckland, New Zealand; These authors contributed equally.
³ Department of Pathology, Dunedin School of Medicine, University of Otago, 270 Great King Street, Dunedin 9054, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, Level, 3A Symonds Street, Auckland, New Zealand.
⁴ Melanoma Immunology and Oncology Group, The Centenary Institute, University of Sydney, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia.
⁵ Department of Pathology, Dunedin School of Medicine, University of Otago, 270 Great King Street, Dunedin 9054, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, Level, 3A Symonds Street, Auckland, New Zealand; Senior author.
⁶ Melanoma Immunology and Oncology Group, The Centenary Institute, University of Sydney, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia; Senior author. Electronic address: p.hersey@centenary.org.au.

PMID: 30853334
DOI: 10.1016/j.it.2019.02.004

Free article

Review

Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy

Abdullah Al Emran et al. Trends Immunol. 2019 Apr.

Free article

. 2019 Apr;40(4):328-344.

doi: 10.1016/j.it.2019.02.004. Epub 2019 Mar 7.

Authors

Abdullah Al Emran¹, Aniruddha Chatterjee², Euan J Rodger³, Jessamy C Tiffen⁴, Stuart J Gallagher⁴, Michael R Eccles⁵, Peter Hersey⁶

Affiliations

¹ Melanoma Immunology and Oncology Group, The Centenary Institute, University of Sydney, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia; These authors contributed equally.
² Department of Pathology, Dunedin School of Medicine, University of Otago, 270 Great King Street, Dunedin 9054, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, Level, 3A Symonds Street, Auckland, New Zealand; These authors contributed equally.
³ Department of Pathology, Dunedin School of Medicine, University of Otago, 270 Great King Street, Dunedin 9054, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, Level, 3A Symonds Street, Auckland, New Zealand.
⁴ Melanoma Immunology and Oncology Group, The Centenary Institute, University of Sydney, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia.
⁵ Department of Pathology, Dunedin School of Medicine, University of Otago, 270 Great King Street, Dunedin 9054, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, Level, 3A Symonds Street, Auckland, New Zealand; Senior author.
⁶ Melanoma Immunology and Oncology Group, The Centenary Institute, University of Sydney, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia; Senior author. Electronic address: p.hersey@centenary.org.au.

PMID: 30853334
DOI: 10.1016/j.it.2019.02.004

Abstract

Methylation of DNA at CpG sites is the most common and stable of epigenetic changes in cancer. Hypermethylation acts to limit immune checkpoint blockade immunotherapy by inhibiting endogenous interferon responses needed for recognition of cancer cells. By contrast, global hypomethylation results in the expression of programmed death ligand 1 (PD-L1) and inhibitory cytokines, accompanied by epithelial-mesenchymal changes that can contribute to immunosuppression. The drivers of these contrasting methylation states are not well understood. DNA methylation also plays a key role in cytotoxic T cell 'exhaustion' associated with tumor progression. We present an updated exploratory analysis of how DNA methylation may define patient subgroups and can be targeted to develop tailored treatment combinations to help improve patient outcomes.

Keywords: DNA methylation; PD-L1; PD1; T cell exhaustion; biomarker; epigenetic remodeling; immune checkpoint blockade; melanoma; resistance; viral mimicry.

PubMed Disclaimer

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy

Affiliations

Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials